Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

DRUG

Bright Minds Biosciences (DRUG)

Bright Minds Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DRUG
DateTimeSourceHeadlineSymbolCompany
27/02/202412:18Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:DRUGBright Minds Biosciences Inc
27/02/202412:10Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:DRUGBright Minds Biosciences Inc
13/02/202413:56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
19/01/202404:57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:DRUGBright Minds Biosciences Inc
30/12/202308:30Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:DRUGBright Minds Biosciences Inc
08/12/202322:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
07/12/202309:08PR Newswire (Canada)Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementNASDAQ:DRUGBright Minds Biosciences Inc
09/08/202306:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
08/08/202320:50GlobeNewswire Inc.Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101NASDAQ:DRUGBright Minds Biosciences Inc
21/07/202303:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
20/07/202320:50GlobeNewswire Inc.Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101NASDAQ:DRUGBright Minds Biosciences Inc
13/07/202306:55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
11/07/202320:50GlobeNewswire Inc.Bright Minds Announces Effective Date of Share ConsolidationNASDAQ:DRUGBright Minds Biosciences Inc
23/06/202305:37Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
22/06/202320:50GlobeNewswire Inc.Bright Minds Announces Proposed Share ConsolidationNASDAQ:DRUGBright Minds Biosciences Inc
16/05/202307:26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
19/04/202320:50GlobeNewswire Inc.Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202NASDAQ:DRUGBright Minds Biosciences Inc
10/04/202322:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
10/04/202320:50GlobeNewswire Inc.Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchNASDAQ:DRUGBright Minds Biosciences Inc
03/03/202306:38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
27/02/202322:50GlobeNewswire Inc.Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023NASDAQ:DRUGBright Minds Biosciences Inc
17/02/202322:50GlobeNewswire Inc.Bright Minds Biosciences Announces Non-Executive Director AppointmentNASDAQ:DRUGBright Minds Biosciences Inc
09/02/202309:25Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
09/02/202308:05GlobeNewswire Inc.Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee RequirementsNASDAQ:DRUGBright Minds Biosciences Inc
08/02/202309:16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
28/01/202308:05GlobeNewswire Inc.Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:DRUGBright Minds Biosciences Inc
10/01/202308:05GlobeNewswire Inc.Bright Minds Biosciences Announces Resignation of Board MemberNASDAQ:DRUGBright Minds Biosciences Inc
06/12/202222:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
03/12/202211:06GlobeNewswire Inc.Bright Minds Biosciences Announces Closing of Non-Brokered Private PlacementNASDAQ:DRUGBright Minds Biosciences Inc
28/11/202222:50GlobeNewswire Inc.Bright Minds Biosciences Announces Non-Brokered Private PlacementNASDAQ:DRUGBright Minds Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:DRUG